This post is from a suggested group
Bronchopulmonary Dysplasia Drug: Advancing Care for the Smallest Fighters
Bronchopulmonary Dysplasia (BPD) is a condition that most people have never heard of, yet it touches the lives of thousands of families every year. It primarily affects premature infants whose lungs are not fully developed at birth. These newborns often require oxygen therapy or mechanical ventilation to survive their earliest days, but the very treatments that save their lives can also place stress on fragile lung tissue. Over time, this can lead to inflammation and long-term breathing complications known as bronchopulmonary dysplasia.
For parents and caregivers, the journey begins in neonatal intensive care units, where every breath a baby takes feels like a milestone. Doctors and researchers have spent decades trying to improve outcomes for these infants, and drug development has become a central part of that effort. Today, therapies designed for BPD focus on reducing lung inflammation, supporting lung growth,…